- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02142309
Glycemic Durability After Metformin Failure (AMAZING)
Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin on Durability of Glycemic Control After Metformin Failure in Type 2 Diabetes
Type 2 diabetes is epidemic and its treatment has become more and more difficult. Consensus algorithms have been developed to help clinicians to select among the numerous medications and their combinations for achieving and maintaining a target glycated hemoglobin A1c (HbA1c) of <7%.
AMAZING, a pragmatic clinical trial, aims to compare commonly used oral diabetes medications, when combined with metformin, on glycemia-lowering effectiveness.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
- Source data verification: paper or electronic medical records.
- Statistical analysis: All analyses will compare the randomly assigned treatment groups under the intention- to-treat principle
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Naples, Italien, 80138
- Aktiv, ikke rekrutterende
- Department of Geriatrics and Metabolic Diseases
-
Naples, Italien, 80138
- Rekruttering
- Katherine Esposito
-
Kontakt:
- Maria Ida Maiorino, MD
- E-mail: mariaida.maiorino@unina2.it
-
Underforsker:
- Giuseppe Bellastella, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Newly-diagnosed, type 2 diabetic patients, failing to diet
Exclusion Criteria:
- Suspected type 1 diabetes or secondary diabetes resulting from specific causes
- Current or previous (within past 3 months) treatment with any investigational drug
- Any major cardiovascular event in previous year
- Plans for pregnancy during the course of the study for women of childbearing potential
- Serum creatinine level >1.3 mg/dL in women and >1.4 mg/dL in men
- History of cancer, other than nonmelanoma skin cancer, that required therapy in the 5 years before randomization
- Treatment with oral, loal, systemic glucocorticoids 14. Treatment with atypical antipsychotics
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Glimepiride
up to 4 mg/day
|
Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
|
Eksperimentel: Vildagliptin
50 mg bid
|
Reduce to 50 mg if estimated glomerular filtration rate (eGFR) <45 mL/min
|
Eksperimentel: Pioglitazone
up to 30 mg/day
|
Start with 15 mg/day and advance to 30 mg/day
|
Eksperimentel: Canagliflozin
300 mg/day
|
Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The primary outcome is maintenance of metabolic control (glycemic durability), defined as time to primary failure with a HbA1c value >7% on maximally tolerated doses of the assigned drug.
Tidsramme: Six years
|
Six years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Continuous glucose monitoring for 72 consecutive hours at least once each year of follow-up
Tidsramme: 6 years
|
6 years
|
Andre resultatmål
Resultatmål |
Tidsramme |
---|---|
Changes of low density lipoprotein cholesterol level from baseline each year of follow up
Tidsramme: 6 years
|
6 years
|
Changes of high density lipoprotein cholesterol level from baseline each year of follow up
Tidsramme: six years
|
six years
|
Changes of triglyceride level from baseline each year of follow up
Tidsramme: 6 years
|
6 years
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Dario Giugliano, MD PHD, University of Campania "Luigi Vanvitelli"
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Glukosemetabolismeforstyrrelser
- Metaboliske sygdomme
- Sygdomme i det endokrine system
- Diabetes mellitus
- Diabetes mellitus, type 2
- Hypoglykæmiske midler
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-arytmimidler
- Enzymhæmmere
- Immunsuppressive midler
- Immunologiske faktorer
- Proteasehæmmere
- Natrium-Glucose Transporter 2-hæmmere
- Dipeptidyl-Peptidase IV-hæmmere
- Pioglitazon
- Glimepirid
- Vildagliptin
- Canagliflozin
Andre undersøgelses-id-numre
- DGM 7-2006
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkendtHER-2-genamplifikation | HER-2 Protein Overekspression
-
The University of Tennessee, KnoxvilleAfsluttetMatematiklærere (2-8 klassetrin) | Matematikstuderende (2-8 klassetrin)Forenede Stater
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkendtSolid tumor | HER-2-genamplifikation | HER2 genmutation | HER-2 Protein OverekspressionKina
-
PowderMedAfsluttet
-
Argorna Pharmaceuticals Co., LTDAfsluttet
-
Argorna Pharmaceuticals Co., LTDAfsluttet
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Aktiv, ikke rekrutterende
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Aktiv, ikke rekrutterende
-
Arcturus Therapeutics, Inc.Afsluttet
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsAfsluttet
Kliniske forsøg med Glimepiride
-
Dong-A ST Co., Ltd.AfsluttetType 2 diabetesKorea, Republikken
-
GlaxoSmithKlineAfsluttetDiabetes mellitus, type 2Korea, Republikken, Malaysia, Filippinerne, Thailand, Den Russiske Føderation, Mexico
-
IKFE Institute for Clinical Research and DevelopmentAfsluttetType 2 diabetes mellitus | Insulin resistensTyskland
-
Laboratorios Silanes S.A. de C.V.AfsluttetType 2 diabetes mellitusMexico
-
Laboratorios Silanes S.A. de C.V.Rekruttering
-
SanofiAfsluttet
-
LG Life SciencesUkendt
-
Kyunghee University Medical CenterSanofi; Korea University Guro Hospital; Hanyang University; The Catholic University... og andre samarbejdspartnereAfsluttetType 2 diabetes mellitus | Pancreas betacelle funktion | GlukotoksicitetKorea, Republikken
-
LG Life SciencesAfsluttetSund og raskKorea, Republikken